These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 24377458)

  • 21. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 22. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
    Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
    Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart rate and heart failure. Not a simple relationship.
    Heusch G
    Circ J; 2011; 75(2):229-36. PubMed ID: 21041970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart rate reduction in heart failure: ivabradine or beta blockers?
    Guglin M
    Heart Fail Rev; 2013 Jul; 18(4):517-28. PubMed ID: 22972475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
    Weeda ER; Nguyen E; White CM
    Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Experience with Ivabradine in Acute Heart Failure.
    Pascual Izco M; Alonso Salinas GL; Sanmartín Fernández M; Del Castillo Carnevalli H; Jiménez Mena M; Camino López A; Zamorano Gómez JL
    Cardiology; 2016; 134(3):372-4. PubMed ID: 27100325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Heart rate: a risk factor or an epiphenomenon?].
    Metra M; Zacà V; Lombardi C; Bugatti S; Dei Cas L
    G Ital Cardiol (Rome); 2010 Mar; 11(3):209-20. PubMed ID: 20550061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
    Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
    Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
    Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
    Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nemaline myopathy and heart failure: role of ivabradine; a case report.
    Sarullo FM; Vitale G; Di Franco A; Sarullo S; Salerno Y; Vassallo L; Baviera EP; Marazia S; Mandalà G; Lanza GA
    BMC Cardiovasc Disord; 2015 Jan; 15():5. PubMed ID: 25597856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivabradine for Treatment of Coronary Artery Disease: From Last Chance Resort to Mainstem of a Reasoned Therapy.
    Lupi A; Rognoni A; Cavallino C; Secco GG; Rosso R; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):4-9. PubMed ID: 25544120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
    Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial.
    Fiuzat M; Wojdyla D; Pina I; Adams K; Whellan D; O'Connor CM
    JACC Heart Fail; 2016 Feb; 4(2):109-115. PubMed ID: 26519996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.